Description: Boston Scientific stock remains under close watch as the company's fair value target holds steady at $126.48 per share. This reflects analysts' continued confidence following the latest results. While the discount rate saw only a marginal shift, most analysts have reaffirmed or raised their price targets, driven by the company's robust performance and positive outlook. Stay tuned to learn the best ways to monitor the evolving narrative and outlook for Boston Scientific as market conditions...

Description: GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.

Description: According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Boston Scientific has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

Description: Encompass Health teams up with Vanderbilt Health to open a new 40-bed inpatient rehabilitation hospital in Tennessee, targeting a 2028 launch.

Description: GE HealthCare unveils Genesis Radiology Workspace, aiming to streamline imaging workflows and boost diagnostic precision.

Description: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Description: The Pediatric Interventional Cardiology Market is poised for significant growth, projected to rise from USD 2.42 billion in 2024 to USD 4.34 billion by 2033, exhibiting a 6.68% CAGR. This expansion is driven by the increasing prevalence of congenital heart defects such as VSD, PDA, and ASD in children. The advent of advanced medical devices and the shift towards non-invasive treatments also contribute to market growth. The U.S. stands out as a key player due to rising infant cardiac abnormalitie

Description: Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.

Description: BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Description: GEHC's $2.3B Intelerad deal aims to accelerate cloud imaging growth, expand outpatient reach and boost its shift toward high-margin SaaS revenue.

Description: The global defibrillator market is forecasted to expand significantly, increasing from US$ 13.74 billion in 2024 to US$ 25.80 billion by 2033, with a steady CAGR of 7.25%. Key drivers include the proliferation of public access defibrillators, expanded ambulance services, and a surge in cardiac ailments. Defibrillators like AEDs and manual devices remain crucial in enhancing survival rates during cardiac arrest emergencies. Top players such as Medtronic, Boston Scientific, and Philips are pivotal

Description: The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.

Description: Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Description: DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.

Description: Boston Scientific (BSX) stock has been on the move recently, catching the attention of investors interested in healthcare innovation. With earnings momentum and strong growth trends, market watchers are looking closely at how the company is positioned for the coming months. See our latest analysis for Boston Scientific. Boston Scientific’s latest share price sits at $96.88, with a year-to-date gain of 8.39%. While the past month has seen a pullback, the stock’s three-year total shareholder...

Description: Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Description: Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: VEEV posts a Q3 earnings beat with stronger subscription growth and higher full-year guidance, highlighting continued momentum.

Description: ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

Description: Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q2 results, though data security threats remain a key risk.

Description: Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.

Description: Boston Scientific (NYSE:BSX) has had a rough three months with its share price down 7.8%. However, a closer look at its...

Description: Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.

Description: Medtronic stock jumped and broke out Tuesday on a "clean beat" driven mainly by its pulsed field ablation technology.

Description: Medtronic shares took off after the company posted better financial results than expected, boosted by what management called a “robust” volume of medical procedures. Medtronic sells surgical tools, plus medical devices that treat heart conditions, diabetes, and a range of other conditions, so it benefits when hospitals do more medical procedures. Investors have closely tracked volumes at Medtronic and its peers since the pandemic, which led to delays in many nonessential surgeries.

Description: Butterfly Network unveils Compass AI to streamline POCUS workflows, boosting documentation compliance and unlocking more revenue for health systems.

Description: The consensus price target hints at a 25.3% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Description: MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.

Description: Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.

Description: ECL's new Cooling as a Service platform targets soaring AI data center demand with integrated site-to-chip efficiency upgrades.

Description: The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.

Description: Intended for use in structural heart procedures, the cardiac imaging catheter is expected to drive growth for Boston Scientific’s Watchman stroke protection device.

Description: Ever wondered if Boston Scientific is a bargain or if the run-up has left it looking pricey? Let’s dig into what’s driving its value right now. Shares have gained 2.7% in the past week and are up 18.0% over the last year, with a huge 139.0% return in three years. This hints at both solid growth and changing investor sentiment. Much of this momentum is being fueled by Boston Scientific’s recent product launches and its acquisition strategy, which have drawn industry attention and optimism...

Description: Boston Scientific recently reported strong quarterly results, surpassing expectations with 21.4% organic sales growth and raising its full-year 2025 outlook for both revenue and adjusted earnings per share. The company also announced an exclusive distribution agreement for the AcuNav 4D ICE catheter with Siemens Healthineers, aimed at supporting the expansion of its Watchman business and procedural adoption. We'll examine how Boston Scientific's improved financial outlook and new partnership...

Description: Boston Scientific anticipates that assisting in commercialising Siemens Healthineers’ 4D ICE catheter will pay dividends for its Watchman business.

Description: HQY's new agentic AI is likely to provide faster, more intuitive support across channels, aiming to boost member satisfaction.

Description: BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.

Description: Boston Scientific Corporation (NYSE:BSX) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 23, UBS maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) shares, and increased its price target to $140 from $135. The price target raise comes after Boston Scientific’s quarterly results, which showed organic sales and […]

Description: BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Description: Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.

Description: PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.

Description: Teleflex posts strong Q3 earnings and revenue beats but trims 2025 outlook, sending shares slightly lower.

Description: Rigetti's Q3 loss is narrower than estimates, but revenues decline as government contract delays hit sales and lower the gross margin.

Description: Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Description: Alcon posts mixed Q3 results as earnings top estimates but revenues miss; new product launches fuel optimism.

Description: When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...

Description: Novatize, a North American B2B eCommerce agency and system integrator, has been recognized as "B2B Agency of the Year" (Mid/Small System Integrator category) at the B2B eCommerce Industry Awards, presented during B2B eCommerce World Americas held in Scottsdale, Arizona.

Description: DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Description: Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Description: PEN's Q3 results impress with double-digit sales growth, margin expansion and a strong 20% stock surge after its earnings beat.

Description: Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.

Description: Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.

Description: BSX sees stronger 2026 prospects for Urology, powered by Axonics integration, innovation and global Stone Management momentum.

Description: Boston Scientific's stock has seen a modest increase in its consensus analyst price target, rising slightly from $126.14 to $126.48. This minor upward adjustment reflects a balance between recent optimism around the company's earnings momentum, strategic acquisitions, and longer-term growth strategy. At the same time, there are more cautious views regarding current valuation and potential market risks. To discover how investors and analysts can keep up with the evolving story of Boston...

Description: AMN Healthcare beats third-quarter 2025 earnings and revenue estimates despite lower margins and year-over-year declines across key segments.

Description: DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.

Description: Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.

Description: - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter of 2025. Business Highlights: BioE

Description: QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.

Description: INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.

Description: PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.

Description: CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.

Description: BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.

Description: DENTSPLY SIRONA shares drop as Q3 earnings miss estimates and 2025 EPS guidance is cut amid segment weakness.

Description: Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.

Description: McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.

Description: STERIS posts strong Q2 results with earnings and revenue beats, margin expansion, and a raised 2026 EPS outlook.

Description: Boston Scientific (BSX) is in the spotlight after reporting third-quarter financial results that show strong sales growth and operational execution. The company has also expanded its medical device offerings in Peripheral Interventions and Cardiology. See our latest analysis for Boston Scientific. Boston Scientific’s recent momentum in sales and product innovation has kept investors optimistic, helping push the stock to a year-to-date share price return of 10.65%. With a 14.41% total...

Description: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Description: Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.

Description: HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.

Description: Masimo beats third-quarter 2025 earnings and revenue estimates as operating margins and profits improve on lower expenses.

Description: Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.

Description: Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.

Description: Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.

Description: Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.

Description: Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.

Description: Here is how ANIXA BIOSCIENCES INC (ANIX) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Description: Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.

Description: BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.

Description: Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.

Description: Analysts spotlight GE Aerospace, Cisco, and HSBC for strong gains, strategic shifts, and margin challenges across key growth areas.

Description: Inspire Medical tops third-quarter 2025 estimates as revenue climbs and gross margin improves, with full-year EPS guidance raised.

Description: The market's expansion is bolstered by major players like Cook Medical, Boston Scientific, and Olympus, engaged in ongoing clinical research and product innovation. Challenges include high equipment costs and the scarcity of trained personnel. Major markets include the US, UK, India, and Saudi Arabia. Endobronchial Ultrasound Biopsy Market Endobronchial Ultrasound Biopsy Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Endobronchial Ultrasound Biopsy Market Size and Share Analysis - Growth

Description: Henry Schein's Q3 earnings and revenues top estimates, lifting the stock as the company raised its 2025 outlook on solid business momentum.

Description: Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.

Description: Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]

Description: Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

Description: The US neurology devices market is driven by rising neurological disorders and tech advancements, supported by government R&D funding. Key segments include neurostimulation and neurosurgery devices, with major players like Medtronic and Boston Scientific. Opportunities lie in innovation and strategic collaborations. U.S. Neurology Devices Market U.S. Neurology Devices Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Neurology Devices Market Size, Share, Growth, Trends, Opportu

Description: Over the past year, many Boston Scientific Corporation ( NYSE:BSX ) insiders sold a significant stake in the company...

Description: MMSI beats third-quarter 2025 estimates on strong revenue and margin growth, prompting a raised full-year outlook across segments.

Description: DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.

Description: Butterfly Network's Q3 loss widens but revenues top estimates, lifting shares as new AI tools and chip advances drive optimism.

Description: Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

Description: Boston Scientific Corp. (NYSE:BSX) is one of the best stocks to buy according to Citadel LLC. On October 22, Josh Jennings, an analyst at TD Cowen, reiterated his $115 price target and Buy rating on the stock after the company reported strong Q3 2025 results. Jennings said the company’s 15.3% organic growth was the highlight of […]

Description: As Boston Scientific has outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Description: Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.

Description: RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.

Description: Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Description: AVTR's Q3 earnings and revenue fell short of estimates, leading the company to cut its full-year 2025 outlook.

Description: DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.

Description: TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.

Description: OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.

Description: Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.

Description: Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.

Description: Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.

Description: BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.

Description: The AI rally has many investors wondering where to turn in anticipation of its end. The medical-device maker is one solid option.

Description: ​Boston Scientific Corporation (NYSE:BSX) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 23, William Plovanic from Canaccord Genuity reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $132. ​The rating comes after the company, on October 22, released results for its fiscal […]

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: CVS shares slip even though Q3 earnings and revenues beat estimates, with the company boosting its 2025 EPS outlook.

Description: GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.

Description: Both Intuitive Surgical and Boston Scientific posted strong Q3 results, but their sharply contrasting growth strategies make them very different investment stories.

Description: Boston Scientific’s third quarter saw a positive market reaction, reflecting operational execution across multiple business units. Management attributed the strong results to broad-based growth, especially in electrophysiology and the WATCHMAN left atrial appendage closure device, which CEO Michael Mahoney called “a gem for Boston Scientific.” The company also noted resilient demand in the U.S. and Asia Pacific, with double-digit growth in Japan and China. Mahoney emphasized that growth was driv

Description: If you are trying to figure out what to do with Boston Scientific stock right now, you are not alone. It is one of those names that investors keep coming back to, especially after a remarkable run in recent years. Just think about it: the stock has climbed an impressive 19.4% in the past year and a staggering 187.3% over five years. Even more, the year-to-date gain of 13.0% and a steady 2.8% in the last 30 days suggest this momentum may have staying power. Behind these moves is a string of...

Description: What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Description: The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory diseases, advancements in nebulizer technology, and an increased focus on home healthcare solutions. Nebulizers offer effective inhalation therapy for conditions like asthma, COPD, and cystic fibrosis. Technological improvements such as smart connectivity and portable designs enhance user convenience,

Description: PAHC vs. BSX: Which Stock Is the Better Value Option?

Description: Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.

Description: The consensus price target hints at a 25.6% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Description: GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.

Description: The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Card

Description: Boston Scientific stock is under fresh scrutiny as analysts adjust their price targets upward. The consensus figure is now $126.14, up from $124.53. This incremental rise reflects optimism fueled by strong quarterly results and revised guidance, balanced against an evolving competitive landscape. Read on to discover how you can stay ahead of future updates as the narrative around Boston Scientific continues to develop. What Wall Street Has Been Saying Analyst sentiment on Boston Scientific...

Description: Boston Scientific reported third-quarter 2025 results that exceeded analyst expectations, with revenue rising to US$5.07 billion and net income increasing to US$755 million, supported by strong performance across multiple segments and regions. The company raised its financial guidance for the fourth quarter and full year 2025, driven by robust growth in its cardiovascular segment, ongoing product innovation like the FARAPULSE system, and the recent acquisition of Nalu Medical expanding its...

Description: Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.

Description: West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.

Description: Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Description: Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Description: Companies in The News Are: BSX, ISRG, BCS, CB

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Boston Scientific (BSX) delivered standout earnings growth, with profits up 18.5% per year over the last five years and a strong 37% gain in the most recent year. Net profit margins rose to 13.5% from 12% previously. Forward-looking guidance points to annual earnings growth of 16.6%, ahead of the US market average, and revenue growth is forecast at 9.6% per year. With the share price trading below analyst targets, investors are likely to view these results as continued evidence of...

Description: Boston Scientific stock jumped Wednesday after its Watchman and electrophysiology franchises helped drive a third-quarter beat.

Description: Boston Scientific Corp (BSX) reports robust operational and organic sales growth, driven by key segments and strategic expansions, despite regional challenges.

Description: Boston achieved a 22.4% growth in its cardiovascular business in Q3, continuing the segment’s growth trend in 2025 due to the ongoing adoption of its Farapulse PFA system.

Description: GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.

Description: Shares of medical device company Boston Scientific (NYSE:BSX) jumped 4.4% in the morning session after the company reported strong third-quarter results that topped Wall Street's forecasts and raised its full-year financial outlook.

Description: Boston Scientific (BSX) raised its full-year guidance on Wednesday as the medical device supplier's

Description: (Updates with latest stock movement in the headline and first paragraph.) Boston Scientific (BSX)

Description: Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.

Description: Strong sales growth in the company’s electrophysiology unit comes amid a market fight between some of the medtech industry’s largest players.

Description: Boston Scientific (BSX) delivered earnings and revenue surprises of +5.63% and +1.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The main US stock measures were trending lower in Wednesday's premarket activity as President Donald

Description: Medical device company Boston Scientific (NYSE:BSX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.

Description: The medical device company recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.

Description: The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share. The medical device manufacturer posted revenue of $5.07 billion in the period, which also beat Street forecasts.

Description: Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted3 EPS of $0.75 for

Description: The U.S. government shutdown continues, but investors won't be completely starved for economic data. Friday brings a delayed look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.

Description: Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen reaffirmed its Buy rating and $115 price target on the company on October 10. According to the firm, the visit strengthened its belief in Boston Scientific’s outlook, which it […]

Description: The U.S. government shutdown continues, but investors won't be completely starved for economic data. Friday brings a delayed look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: Medical device company Boston Scientific (NYSE:BSX) will be announcing earnings results this Wednesday morning. Here’s what to expect.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Here is how Boston Scientific (BSX) and Amarin (AMRN) have performed compared to their sector so far this year.

Description: Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.

Description: The U.S. government shutdown is set to drag into another week, but that doesn’t mean investors will be starved for economic data. Friday brings a delayed look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: As investors enters shutdown week three, a US-China trade war, credit gesticulation, and an incoming oil glut are weighing on the market.

Description: Boston Scientific (BSX) has seen its stock gradually climb in recent weeks, supported by consistent revenue and net income growth. Investors are likely watching the pace of these gains to gauge whether the company’s momentum can be sustained. See our latest analysis for Boston Scientific. After an impressive start to the year, Boston Scientific’s share price now sits at $99.24, posting an 11% return year-to-date. Recent momentum has been steady, supporting a solid 1-year total shareholder...

Description: The U.S. government shutdown is set to drag into another week, but that doesn’t mean investors will be starved for economic data. Next Friday brings a (delayed) look at September’s consumer-price index, a key inflation reading that will factor into the Federal Reserve’s next decision on interest rates.

Description: Nalu’s PNS system complements Boston’s existing neuromodulation portfolio, which includes its WaveWriter Alpha SCS system for chronic spinal pain.

Description: Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: Intuitive Surgical enters Q3 earnings season on strong momentum, backed by robust procedure growth and da Vinci 5 adoption. However, tariff risks and global CapEx constraints remain challenges.

Description: Nalu’s implantable neurostimulation system delivers electrical impulses to treat chronic pain originating from the peripheral nerves.

Description: Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.